



**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:  
Melanie H. Cobb et al.

Serial No.: 09/686,346

Filed: October 10, 2000

For: TAO PROTEIN KINASE POLYPEPTIDES  
AND METHODS OF USE THEREFOR

Group Art Unit: 1652

Examiner: Maryam Monshipouri

Atty. Dkt. No.: UTSD:1276USC1

**CERTIFICATE OF HAND DELIVERY**

I certify that this correspondence is being hand delivered  
for filing to: ATTN: Maryam Monshipouri, Customer  
Service Window, Crystal Plaza 2, 2011 S. Clark Place,  
Lobby, Room 1B03, Arlington, VA, on the date below:

4/5/04  
Date

Signature

**INTERVIEW SUMMARY**

**ATTN: MARYAM MONSHIPOURI**

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Commissioner:

Applicants respectfully submit this Interview Summary regarding a telephonic interview conducted between Examiner Maryam Monshipouri and Applicants' representative, Mark B. Wilson, on March 30, 2004.

On March 30, 2004, Examiner Monshipouri and Applicants' representative, Mark B. Wilson, had a telephonic interview in regard to the above-captioned application. This interview occurred after a series of voice mail messages and brief conversations during the preceding days. The subject of this interview was as follows.

Examiner Monshipouri contacted Mr. Wilson seeking clarification as to why the Sequence Listing filed with the specification on October 10, 2000, contained 28 sequences, and the specification discussed 28 sequences, whereas the Sequence Listing submitted to the Patent and Trademark Office on June 6, 2001, contained only 26 sequences.

After investigation, Mr. Wilson determined that the Sequence Listing submitted to the Patent and Trademark Office on June 6, 2001, was not the proper Sequence Listing for the present case. Rather, this Sequence Listing was the Sequence Listing of U.S. Serial No. 09/060,410, which is now issued as U.S. Patent 6,165,461, of which the present application is a continuation-in-part application. Upon discovering this issue, Mr. Wilson contacted Examiner Monshipouri and reported that it would be necessary for Applicants to submit a further Sequence Listing and computer readable format thereof which contained the 28 sequences originally filed with the specification. Examiner Monshipouri and Mr. Wilson discussed this matter during the telephonic interview of March 30, 2004. At that time, Examiner Monshipouri instructed Mr. Wilson to have prepared a new sequence listing with the correct sequences as originally filed and to have them submitted to the Patent and Trademark Office in the appropriate manner.

Simultaneously herewith, Applicants are submitting a paper copy of the correct Sequence Listing, a computer readable format containing that Sequence Listing, and a proper statement of conformity. The submission of these materials does not result in new matter being entered into the application, because the 28 sequences contained in the Sequence Listing were filed with the application as it was filed on October 10, 2000.

During the interview, Examiner Monshipouri indicated that, upon receipt of this corrected Sequence Listing, she would review matters and take further appropriate action as needed.

It is believed that no fees under 37 C.F.R. §§ 1.16 to 1.21 are occasioned by the filing of this paper; however, should the Commissioner determine otherwise, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No. 50-1212/UTSD:1276USC1.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'MBW', is written over the typed name.

Mark B. Wilson  
Reg. No. 37, 259  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: April 2, 2004



## FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
WWW.FULBRIGHT.COM

MARK B. WILSON  
PARTNER  
MBWILSON@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3035  
TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

April 2, 2004

### CERTIFICATE OF HAND DELIVERY

I certify that this correspondence is being hand delivered for filing to: ATTN: Maryam Monshipouri, Customer Service Window, Crystal Plaza 2, 2011 S. Clark Place, Lobby, Room 1B03, Arlington, VA, on the date below:

4/5/04  
Date

Signature

### ATTN: MARYAM MONSHIPOURI

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 09/686,346 entitled "TAO PROTEIN KINASE POLYPEPTIDES AND METHODS OF USE THEREFOR" – Melanie H. Cobb et al.*  
*Our reference: UTSD:1276USC1*  
*Client reference: UTSD:1276US CIP*

Sir:

Please find enclosed:

- (1) Statement as Required Under 37 C.F.R. § 1.825(a) and (b) and Statement as Required Under 37 C.F.R. § 1.821(g);
- (2) Computer Readable Form of Sequence Listing;
- (3) Paper Copy of Sequence Listing;
- (4) Interview Summary; and
- (5) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Commissioner for Patents  
April 2, 2004  
Page 2

It is believed that no fee is due with this communication, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed document, the Commissioner is authorized to deduct or credit said fees from or to Fulbright & Jaworski Deposit Account No. 50-1212/UTSD:1276USC1.

Respectfully submitted,

A handwritten signature in black ink, appearing to be 'MBW', written over a horizontal line.

Mark B. Wilson  
Reg. No. 37,259

MBW/mar  
Encl: as noted